IMV Inc. (IMV) Reports Q3 Loss of $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
November 12, 2020 7:05 AM ESTIdentification of PD-L1 as a potential Biomarker with 86% of clinical responses in patients with r/r DLBCL in our combination trial with Mercks Keytruda® Cash and cash equivalents of $54.7M as of September 30th, 2020 Expanded Board of Directors and strengthened management team Reviewing data presented at SITC on a conference call and webcast today at 8:00 a.m. ET
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (the Company or IMV) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies... More
